Pharmaceutical Innovation
-

Novo Nordisk Gains Momentum with GLP-1 Drug Expansion
The success of GLP-1 therapies like Ozempic and Wegovy has propelled Novo Nordisk’s stock, reflecting surging global demand for obesity solutions.
-

Novo Nordisk Boosts Oral GLP-1 Production Amid Intensifying Competition
Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.
